Literature DB >> 1409209

Cytolytic anticardiac membrane antibodies in the pathogenesis of myopericarditis.

B Maisch1, L Drude, C Hengstenberg, G Hufnagel, U Schönian, D Schwab.   

Abstract

Antisarcolemmal (ASAs) and antimyolemmal antibodies (AMLAs) are serological hallmarks of inflammatory heart muscle disease. They occur in a similar incidence in postcardiac injury syndromes, sarcoid heart disease or in dilated and hypertrophic cardiomyopathy. Rarely but still notably they are found with increasing age or in coronary artery disease. We therefore examined whether they are truly pathogenetic or whether they also possess properties of 'natural antibodies'. AMLAs and ASAs, like natural antibodies, have specificity for preserved structures on the membrane; they possess cross-reactivity and increase with age. In contrast to natural antibodies, however, they occur frequently after viral stimulation or other forms of trauma, are more often of the IgG and IgA than of the IgM isotype and fix complement in the acute stage of the disease. They also possess cytolytic and cytotoxic properties when incubated in vitro with isolated heart muscle cells. Antigenic mimicry has been demonstrated to be operative, since they are cross-reactive to viral proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1409209

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  8 in total

Review 1.  [Therapy of dilated cardiomyopathies with and without inflammation].

Authors:  G Hufnagel; S Pankuweit; B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

2.  Recurrent pericarditis in children: elevated cardiac autoantibodies.

Authors:  R Dalla Pozza; D Hartl; S Bechtold; S Urschel; R Kozlik-Feldmann; S Pankuweit; B Belohradsky; H Netz
Journal:  Clin Res Cardiol       Date:  2006-12-22       Impact factor: 5.460

Review 3.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 4.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

5.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

Review 6.  Mechanisms of alterations in cardiac membrane Ca2+ transport due to excess catecholamines.

Authors:  K S Dhalla; H Rupp; R E Beamish; N S Dhalla
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

7.  Anticardiac Antibodies in Patients with Chronic Pericardial Effusion.

Authors:  Konstantinos Karatolios; Sabine Pankuweit; Anette Richter; Volker Ruppert; Bernhard Maisch
Journal:  Dis Markers       Date:  2016-01-28       Impact factor: 3.434

Review 8.  Triggers of Inflammatory Heart Disease.

Authors:  Ninaad Lasrado; Bharathi Yalaka; Jay Reddy
Journal:  Front Cell Dev Biol       Date:  2020-03-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.